Trial Profile

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary) ; Phenprocoumon
Indications Ischaemic stroke
Focus Therapeutic Use
Acronyms RELOAD
Sponsors Bayer

Most Recent Events

30 Aug 2017 Results assessing characteristics of 15mg od rivaroxaban presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
30 Aug 2017 Baseline charecteristics (n=33668) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
06 Mar 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com